This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The analysis of effectiveness was conducted on an intention to treat basis and included all randomised patients. The primary health outcome was the time to the first event of doubling of serum creatinine, ESRD or death. The groups were shown to be comparable at baseline.
Effectiveness results
Over 3.6 years, treatment with losartan-CAHT reduced the number of days with ESRD by 33.6 (95% confidence interval, CI: 10.9 -56.3), or 31% per patient, compared with placebo-CAHT treatment.
Twenty-four per cent of the patients in the placebo group and 19% of patients in the losartan group withdrew from the study therapy due to side effects. In terms of the incidence of adverse effects, no statistically significant difference between the groups was observed.
Treatment with losartan was associated with a relative risk reduction in the incidence of ESRD of 29%, (p=0.002), compared with placebo treatment. It was also associated with a reduction in risk of 25%, (p=0.006), for a doubling of serum creatinine concentration.
In terms of overall mortality, no statistically significant difference between the groups was observed.
Clinical conclusions
AIIAs, which include losartan, are associated with reductions in the number of days with ESRD and are recommended as first-line therapy for patients with nephropathy, hypertension and Type 2 diabetes.
Measure of benefits used in the economic analysis
No summary measure of health benefit was used in the economic analysis. Hence, a cost-consequences analysis was performed.
Direct costs
The resource use quantities and the costs were not reported separately. The study included those costs relevant to a health care payer, such as a managed care organisation. The costs of ESRD care and losartan therapy were derived from published data. The costs were discounted at a rate of 3% per annum. No explicit justification was provided for the choice of discount rate, but it was one commonly used in US-based economic evaluations. The costs were reported as year 2001 US dollars. The method of adjusting for inflation was not specified. Patients who withdrew from the study therapy were assumed not to incur further mediation costs. The costs of adverse events and other medications were assumed to be equal between the two groups. The costs of monitoring serum creatinine and potassium levels were omitted as patients with diabetes and renal disease would be routinely monitored (see Other Publications of Related Interest).
Statistical analysis of costs
The cost data were treated deterministically. This was appropriate for the simple within-trial analysis performed using an outside point estimate of cost. Compared with placebo, treatment with losartan was found to reduce the costs associated with ESRD by $5,144 per patient over 3.5 years, (p=0.003). If an analysis that calculated patient-level costs had been possible, the associated variance in the mean cost estimated for each group may have altered the outcome of a
